Earlier in March 2026, Guardant Health announced that its FDA-approved Shield blood-based colorectal cancer screening test is now widely available for physician order through Quest Diagnostics’ ...

The deal expands the local firm’s footprint as Quest exits market. #NewsismyBusiness - Stay updated with the latest Puerto ...

SECAUCUS, N.J., Aug. 5, 2025 /PRNewswire/ -- Quest Diagnostics (DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of ...

TEMPE, Ariz.--(BUSINESS WIRE)--Sonora Quest Laboratories has established a new partnership to reduce the burden of rising out-of-pocket medical costs on its patients. The company has teamed up with ...

Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging ...

Event overview and recent stock performance Quest Diagnostics (DGX) has been drawing attention after recent share price moves ...

Quest Diagnostics (NYSE:DGX) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while ...

[Updated 5/15/2020] Is Quest Diagnostics Or LabCorp The Better Diagnostic Play In The COVID Era? As the U.S. re-opens its economy while trying to contain the spread of the contagious viral infection, ...

Quest Diagnostics named Dr. Yuri Fesko, a seasoned health care executive and oncologist, its new senior vice president and chief medical officer. In a Dec. 20 press release announcing the appointment, ...